Isicom (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, replenishing the deficient neurotransmitter in Parkinson's disease. Carbidopa blocks the peripheral enzyme that would otherwise convert levodopa before it reaches the brain, increasing central availability and reducing peripheral side effects.

The dosage of Isicom is individualized by the prescribing clinician based on disease severity, patient age, and response to therapy. Physicians determine the appropriate strength and frequency, and patients should follow the prescribed regimen without making adjustments on their own.

Safety data for levodopa/carbidopa in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Isicom, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Isicom combines levodopa with carbidopa, offering a direct dopamine replacement strategy, whereas other agents such as dopamine agonists or MAO‑B inhibitors modulate dopamine pathways indirectly. The levodopa/carbidopa combo generally provides stronger symptomatic relief but may have a higher incidence of motor complications compared with some alternatives.

Isicom should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Isicom is taken orally, usually with a glass of water. It can be taken with or without food, but high‑protein meals may affect absorption, so patients are often advised to maintain a consistent eating pattern around dosing times as directed by their physician.

Serious risks include the development of dyskinesias (involuntary movements), severe orthostatic hypotension, hallucinations or other psychiatric disturbances, and rare occurrences of neuroleptic malignant syndrome. Patients should be monitored closely for these events, especially after dose changes.

Isicom is contraindicated in patients with known hypersensitivity to levodopa or carbidopa, those taking non‑selective MAO inhibitors, and individuals with narrow‑angle glaucoma that could be aggravated by the drug. Clinicians should also exercise caution in patients with severe cardiovascular disease or uncontrolled hypertension.